New obesity drug AMG 133 enters human testing

NCT ID NCT06976372

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial tested an experimental drug called AMG 133 in 120 adults with overweight or obesity. Participants received multiple doses of the drug or a placebo to see how the body processes it and to check for safety issues. The study did not aim to measure weight loss directly, but to gather important information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMG 133 (an experimental drug given as a shot under the skin)
What this could lead to: If successful, this could lead to a new weight-loss medication for people with overweight or obesity.
What could go wrong: This is an early Phase 1 study focused on drug levels and safety, not weight loss. The drug may cause side effects or not work as hoped in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

CenExel

Anaheim, California, 92801, United States
CenExel Collaborative Neuroscience Research, LLC Los Alamitos

Los Alamitos, California, 90720, United States
Fortrea Clinical Research Unit - Dallas

Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.